Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 14, 2016

RANCHO CUCAMONGA, Calif., March 11, 2016 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2015 ended December 31, 2015, after the market closes on Monday, March 14, 2016, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 65494178.

The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.

Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.

This press release contains forward-looking statements, including statements relating to Amphastar Pharmaceuticals. These statements are not historical facts but rather are based on Amphastar Pharmaceuticals’ current expectations, estimates and projections regarding Amphastar Pharmaceuticals’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements. These statements are only predictions and as such are not guarantees of future performance, and they involve risks, uncertainties, and assumptions that are difficult or impossible to predict. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Amphastar Pharmaceuticals’ filings with the SEC.

William J. Peters
Chief Financial Officer
(909) 980-9484